Botulinum Toxin Treatment to Reduce Inflammation in Adults with Hidradenitis Suppurativa Ages 18 to 75

What this Trial Is About

Researchers are exploring the role of TRPV1 nociceptors in the development of Hidradenitis Suppurativa HS, a chronic inflammatory skin disease driven by type-17 inflammation. The study aims to test whether blocking neuropeptide activity with botulinum toxin can reduce harmful inflammation in HS patients. This investigation builds on previous findings from both mouse and human studies. Participants will receive botulinum toxin injections 50 units per axilla, divided into 10 injections of 0.1 mL administered directly into the affected skin areas. Skin biopsies will be taken before and 1 to 2 months after treatment to analyze changes in immune cells and inflammation markers. The study focuses on examining the effects of this treatment on inflammatory skin cells using advanced laboratory techniques. Throughout the study, participants will have skin biopsies collected to measure specific immune cells like dendritic cells, macrophages, and T cells before and after treatment. Researchers will use flow cytometry, transcriptomic, and microscopic analyses to assess inflammation levels. The main outcome is to quantify changes in these immune cells within 1 to 2 months following the botulinum toxin treatment. The study is expected to continue until April 2028.

Botulinum Toxin Therapy in Hidradenitis Suppurativa